Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun;22(6):559-70.
doi: 10.1002/pds.3437.

Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies

Cristina Varas-Lorenzo, Nuria Riera-Guardia, Brian Calingaert, Jordi Castellsague, Francesco Salvo, Federica Nicotra, Miriam Sturkenboom, Susana Perez-Gutthann
Free PMC article

Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies

Cristina Varas-Lorenzo et al. Pharmacoepidemiol Drug Saf. 2013 Jun.
Free PMC article

Abstract

Objective: To conduct a systematic review of observational studies on the risk of acute myocardial infarction (AMI) with use of individual nonsteroidal anti-inflammatory drugs (NSAIDs).

Methods: A search of Medline (PubMed) for observational studies published from 1990 to 2011 identified 3829 articles; 31 reported relative risk (RR) of AMI with use of individual NSAIDs versus nonuse of NSAIDs. Information abstracted in a standardized form from 25 publications was used for the meta-analysis on 18 independent study populations.

Results: Random-effects RR (95% confidence interval (CI)) was lowest for naproxen 1.06 (0.94–1.20), followed by celecoxib 1.12 (1.00–1.24), ibuprofen 1.14 (0.98–1.31), meloxicam 1.25 (1.04–1.49), rofecoxib 1.34 (1.22–1.48), diclofenac 1.38 (1.26–1.52), indometacin 1.40 (1.21–1.62), etodolac 1.55 (1.16–2.06), and etoricoxib 1.97 (1.35–2.89). Heterogeneity between studies was present. For new users, RRs (95% CIs) were for naproxen, 0.85 (0.73–1.00); ibuprofen, 1.20 (0.97–1.48); celecoxib, 1.23 (1.00–1.52); diclofenac, 1.41 (1.08–1.86); and rofecoxib, 1.43 (1.21–1.66).Except for naproxen, higher risk was generally associated with higher doses, as defined in each study, overall and in patients with prior coronary heart disease. Low and high doses of diclofenac and rofecoxib were associated with high risk of AMI, with dose–response relationship for rofecoxib. In patients with prior coronary heart disease, except for naproxen, duration of use ≤3 months was associated with an increased risk of AMI.

Conclusions: Most frequently NSAIDs used in clinical practice, except naproxen, are associated with an increased risk of AMI at high doses or in persons with diagnosed coronary heart disease. For diclofenac and rofecoxib, the risk was increased at low and high doses.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of identification and selection of studies. Note: the individual NSAIDs used as reference in each of the 11 excluded studies were the following: diclofenac (n = 2); ibuprofen or diclofenac (n = 1); meloxicam (n = 1); rofecoxib (n = 1); celecoxib (n = 2); acetaminophen (n = 1); aspirin (n = 1); non-naproxen NSAIDS (n = 1); non-selective NSAIDS (n = 1)
Figure 2
Figure 2
Pooled relative risk (random effects) of acute myocardial infarction associated with current use of individual NSAIDs relative to NSAID nonuse, according to dose group. AMI = acute myocardial infarction; NSAID = nonsteroidal anti-inflammatory drug; RR = relative risk
Figure 3
Figure 3
Pooled relative risk (random effects) of acute myocardial infarction associated with current use of individual NSAIDs relative to NSAID nonuse according to dose group and duration, in populations with preexisting diagnosed coronary heart disease. Note: Ray et al. presented the effect estimates of three independent cohorts. AMI = acute myocardial infarction; NSAID = nonsteroidal anti-inflammatory drug; RR = relative risk; Duration in months
Figure 4
Figure 4
Summary relative risk of acute myocardial infarction, stroke, or combined cardiovascular endpoints for individual NSAIDs compared with NSAID nonuse from three independent meta-analyses. Data sources: acute myocardial infarction (current meta-analysis), stroke, and combined cardiovascular endpoint
See this image and copyright information in PMC

Comment in

References

    1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520–8. 2 p following 8. DOI: 10.1056/NEJM200011233432103. - DOI - PubMed
    1. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–102. DOI: 10.1056/NEJMoa050493. - DOI - PubMed
    1. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–80. DOI: 10.1056/NEJMoa050405. - DOI - PubMed
    1. Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol. 2006;98:266–74. DOI: 10.1111/j.1742-7843.2006.pto_302.x. - DOI - PubMed
    1. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302–8. DOI: 10.1136/bmj.332.7553.1302. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances